Search

Search Results

• 

  25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo^1|2, Carlo Resteghini^1|2, Sara Farinatti^1|2, Andrea Alberti³, Valeria Tovazzi³, Paola Queirolo⁴, Maristella Saponara⁴, Giuseppe Argenziano⁵, Riccardo Marconcini⁶, Ketty Peris⁷, Paola Savoia⁸, Maria Chiara Tronconi¹, Iris Zalaudek⁹, Paolo Ascierto¹⁰, Francesco Spagnolo¹¹, Luigi Lorini¹, Cristina Gurizzan¹, Paolo Bossi^1|2 | ¹Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano ^MI; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; ³Medical Oncology Unit, ASST Spedali Civili, Brescia; ⁴Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; ⁵Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁶Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Department of Health Sciences, University of Eastern Piedmont, Novara; ⁹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; ¹⁰Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; ¹¹Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10767

  320
• 

  30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti^1|2, Giuseppe Agenziano³, Emi Dika^4|5, Emanuela Passoni⁶, Ketty Peris⁷, Pietro Quaglino⁸, Paola Queirolo⁹, Massimiliano Scalvenzi¹⁰, Iris Zalaudek¹¹, Luigi Lorini¹¹, Cristina Gurizzan¹, Monica Variolo^1|2, Paolo Bossi*^1|2, Carlo Resteghini*^1|2 | ¹Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; ²Department of Biomedical Sciences, Humanitas University, Rozzano ^MI; ³Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁴Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; ⁵Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; ⁶Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Dermatologic Clinic, University of Turin Medical School, Turin; ⁹Medical Oncology Unit; ¹⁰Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; ¹¹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10772

  337
• 

  23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*¹, Teresa Amaral*², Piotr Rutkowski*³, Marie-Lena Rasch², Naima Benannoune⁴, Patricio Serra⁵, Maria Grazia Vitale⁶, Diana Giannarelli⁷, Ana Maria Arance⁸, Eva Munoz Couselo⁹, Bart Neyns¹⁰, Iris Dirven¹¹, Marco Tucci¹², Michele Guida¹³, Francesco Spagnolo¹⁴, Ernesto Rossi¹⁵, Paola Queirolo¹⁶, Pietro Quaglino¹⁷, Roberta Depenni¹⁸, Joanna Placzke³, Anna Maria Di Giacomo¹⁹, Michele Del Vecchio²⁰, Alice Indini²⁰, Ines Pires da Silva²¹, Alexander M. Menzies²², Angela Hong²³, Paul Lorigan⁵, Caroline Robert²⁴, Georgina V. Long²², Paolo A. Ascierto⁶, Mario Mandalà²⁵ | ¹Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; ²Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. ³Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. ⁴Gustave Roussy Cancer Campus, Villejuif, France. ⁵The University of Manchester, Manchester, UK. ⁶Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; ⁷Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; ⁸Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; ⁹Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; ¹⁰Department of Medical Oncology, UZ Brussel, Brussels, Belgium. ¹¹Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; ¹²Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. ¹³Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. ¹⁴IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; ¹⁵Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; ¹⁶IEO European Institute of Oncology, IRCCS, Milan, Italy. ¹⁷Department of Dermatology, University of Turin, Turin, Italy. ¹⁸University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; ¹⁹Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. ²⁰Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²¹Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; ²²Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; ²³Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; ²⁴Gustave Roussy and Paris-Saclay University, Villejuif, France; ²⁵Unit of Medical Oncology, University of Perugia, Perugia, Italy. ^§ on behalf of the Italian Melanoma Intergroup - IMI.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10765

  292